Heterocyclic Building Blocks-isoxazole

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4369-55-5,5-Amino-3-phenylisoxazole,as a common compound, the synthetic route is as follows.

adding 1.0 equiv. (0.2 mmol) of an oxazole ring to a schlenk tube, and adding 2 mL of analytically pure ethanol,A 1% equiv. ruthenium catalyst was reacted under green light for 24-72 hours. After the reaction is completed, the solvent is removed by a rotary evaporator, and the organic phase is extracted three times with water and dichloromethane, and the organic phase is dried over anhydrous sodium sulfate, and the solvent is evaporated and then subjected to column chromatography (dichloromethane/methanol) Amine heterocyclic propylene compound.

As the paragraph descriping shows that 4369-55-5 is playing an increasingly important role.

Reference£º
Patent; Nanjing Tech University; Jiang Yaojia; Chen Yang; Luo Deping; (7 pag.)CN110041237; (2019); A;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3209-71-0,Isoxazole-3-carboxylic Acid,as a common compound, the synthetic route is as follows.

A solution of isoxazole-3-carboxylic acid (10 mg, 0.084 mmol), HATU (32 mg, 0.084 mmol), triethylamine (30 ul, 0.212 mmol), 3-methyl-4-(7-methylbenzo[d]oxazol-2-yl)aniline (20 mg, 0.084) and catalytic amount of DMAP in THF (1 mL) was stirred at 65 C for 48 h. The reaction mixture was diluted with DCM, washed with saturated solution of NaHCO3 and brine. The organic solution was, dried over Na2SO4, decanted and evaporated under reduced pressure. The crude was purified by column chromatography on silica gel using 1:4 EtOAc:Hexane as mobile phase and the obtained product was triturated in hexane, filtered and dried to give N-(3-methyl-4-(7- methylbenzo[d]oxazol-2-yl)phenyl)isoxazole-3-carboxamide (3 mg, 10%). UPLC-MS (Acidic Method, 4 min): rt 2.12 min, m/z 334.1 [M+H]+ 1H NMR (400 MHz, METHANOL-d4) d ppm 7.32 (d, J=1.6 Hz, 1H), 6.63 (d, J=8.5 Hz, 1H), 6.26-6.32 (m, 2H), 6.02 (d, J=7.9 Hz, 1H), 5.71-5.77 (m, 1H), 5.65-5.69 (m, 1H), 5.40 (d, J=1.6 Hz, 1H), 1.27 (s, 3H), 1.06 (s, 3H).

As the paragraph descriping shows that 3209-71-0 is playing an increasingly important role.

Reference£º
Patent; JAGUAHR THERAPEUTICS PTE LTD; METE, Antonio; HITCHIN, James, R.; GRAHAM, Mark; (46 pag.)WO2020/43880; (2020); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3209-71-0,Isoxazole-3-carboxylic Acid,as a common compound, the synthetic route is as follows.

A solution of 3-isoxazolecarboxylic acid (500 mg, 4.42 mmol, commercially available from e.g. Manchester Organics, Bio-Farma or APAC) in dry dichloromethane (DCM) (14.700 ml) was stirred at room temeprature under an atmosphere of argon. EDC (1017 mg, 5.31 mmol) and HOBt (339 mg, 2.21 1 mmol) were added to the stirred soltuion and the resulting solution was stirred for 3/4 hour. After this time, 1 ,1- dimethylethyl hydrazinecarboxylate (701 mg, 5.31 mmol) was added to the stirred solution and strring continued for a further 18 hours at room temperature (overnight). The reaction mixture was partitioned between DCM (~ 20 ml) and saturated sodium bicarbonate solution (~ 20 ml). The aqueous phase was extracted with DCM (2 x 20 ml) and the combined organic extracts washed with saturated brine (~ 50 ml), dried over sodium sulphate, evaporated in vacuo and dried (vacuum oven, 40 0C, 72 hr) to afford the crude product as a brown oil. This was purified via Biotage SP4 (2-20 % MeOH/DCM; 100g SNAP Biotage column; 12 CV) to afford the required product as an orange oil in 510.6 mg, which was used without further purification in the next step. LCMS: [M-Boc+H]+ m/z = 128.0; RT. = 0.62-0.63 min.

3209-71-0 Isoxazole-3-carboxylic Acid 11286453, aIsoxazoles compound, is more and more widely used in various.

Reference£º
Patent; GLAXO GROUP LIMITED; DEAN, David Kenneth; MUNOZ-MURIEDAS, Jorge; SIME, Mairi; STEADMAN, Jon Graham Anthony; THEWLIS, Rachel Elizabeth Anne; TRANI, Giancarlo; WALTER, Daryl Simon; WO2010/125102; (2010); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

14441-90-8, 5-Phenylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

into a 50-mL round-bottom flask, was placed a solution of 5- phenyl-1,2-oxazole-3-carboxylic acid (177.7 mg, 0.94 mmol, 1.00 eq.), 1-[1-[trans-3- aminocyclobutyl]- 1 H-pyrazol-3-yl]ethan- 1 -ol hydrochloride (246 mg, 1.13 mmol, 1.20 eq.),HATU (428.8 mg, 1.13 mmol, 1.20 eq.) and DIEA (363.9 mg, 2.82 mmol, 3.00 eq.) in DMF(10 mL). The resulting solution was stirred for 2 hours at room temperature. The reaction was then quenched by the addition of 20 mL of water. The resulting solution was extracted with ethyl acetate (3×20 mL) and the organic combined layers were dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a Prep-TLC with ethylacetate/petroleum ether (2:1). This resulted in 189 mg (57%) of 5 -phenyl-N-[trans-3 -[3 -(1- hydroxyethyl)- 1 H-pyrazol- 1 -yl]cyclobutyl] -1 ,2-oxazole-3 -carboxamide as a off-white solid.

As the paragraph descriping shows that 14441-90-8 is playing an increasingly important role.

Reference£º
Patent; BASTOS Cecilia M.; MUNOZ Benito; TAIT Bradley; WO2015/196071; A1; (2015);,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

21169-71-1, Isoxazole-5-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Compounds were synthesized in solution phase using Boc-protected amino acids on 100-200mg scale. Firstly, the amino acid (1.2-1.5equiv) was activated with HBTU (1.5equiv) and DIPEA (1.5equiv) as 0.2-0.5M solution in DMF for 10min. Then the solution was added to an amino group bearing C-terminal moiety (R1R2NH) and the mixture was stirred for a minimum of 1h at room temperature. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO3 (2¡Á). The organic extracts were dried over MgSO4, filtered and evaporated in vacuo. The crude product was then treated with 20% TFA in DCM and stirred for 1-2h to remove the Boc group. TFA was removed by evaporating the reaction mixture under a stream of N2. The residue was dissolved in DCM and washed with saturated NaHCO3 (2¡Á). DCM phase was dried with MgSO4, filtered and evaporated in vacuo. Subsequent N-Boc-amino acids and amines were sequentially coupled under the same conditions. Each coupling reaction was monitored by ESMS, with most reactions going to completion overnight. All final compounds were purified on rpHPLC (97% by analytical HPLC) and fully characterized by NMR and HRMS (yields between 30% and 40%).

The synthetic route of 21169-71-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Yau, Mei-Kwan; Liu, Ligong; Lim, Junxian; Lohman, Rink-Jan; Cotterell, Adam J.; Suen, Jacky Y.; Vesey, David A.; Reid, Robert C.; Fairlie, David P.; Bioorganic and Medicinal Chemistry Letters; vol. 26; 3; (2016); p. 986 – 991;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.21169-71-1,Isoxazole-5-carboxylic acid,as a common compound, the synthetic route is as follows.

General procedure: Compounds were synthesized in solution phase using Boc-protected amino acids on 100-200mg scale. Firstly, the amino acid (1.2-1.5equiv) was activated with HBTU (1.5equiv) and DIPEA (1.5equiv) as 0.2-0.5M solution in DMF for 10min. Then the solution was added to an amino group bearing C-terminal moiety (R1R2NH) and the mixture was stirred for a minimum of 1h at room temperature. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO3 (2¡Á). The organic extracts were dried over MgSO4, filtered and evaporated in vacuo. The crude product was then treated with 20% TFA in DCM and stirred for 1-2h to remove the Boc group. TFA was removed by evaporating the reaction mixture under a stream of N2. The residue was dissolved in DCM and washed with saturated NaHCO3 (2¡Á). DCM phase was dried with MgSO4, filtered and evaporated in vacuo. Subsequent N-Boc-amino acids and amines were sequentially coupled under the same conditions. Each coupling reaction was monitored by ESMS, with most reactions going to completion overnight. All final compounds were purified on rpHPLC (97% by analytical HPLC) and fully characterized by NMR and HRMS (yields between 30% and 40%).

As the paragraph descriping shows that 21169-71-1 is playing an increasingly important role.

Reference£º
Article; Yau, Mei-Kwan; Liu, Ligong; Lim, Junxian; Lohman, Rink-Jan; Cotterell, Adam J.; Suen, Jacky Y.; Vesey, David A.; Reid, Robert C.; Fairlie, David P.; Bioorganic and Medicinal Chemistry Letters; vol. 26; 3; (2016); p. 986 – 991;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.21169-71-1,Isoxazole-5-carboxylic acid,as a common compound, the synthetic route is as follows.

EXAMPLE 24 (S)-(-)-N-[[3-[4-[1-(Isoxazole-5-carbonyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide A solution of isoxazole-5-carboxylic acid (79 mg) and 1,1′-carbonyldiimidazole (80 mg) in dry tetrahydrofuran (2.0 mL) is stirred am ambient temperature for one hour, and a solution of (S)-(-)-N-[[2-oxo-3-[4-(4-piperidinyl)-3-fluorophenyl]-5-oxazolidinyl]methyl]acetamide (EXAMPLE 20, 150 mg) in dry tetrahydrofuran (6.0 mL) is added. The mixture is then stirred at ambient temperature for 19 hours, concentrated under reduced pressure, diluted with methylene chloride (20 mL), washed with saturated aqueous sodium bicarbonate (10 mL), water (10 mL) and saline (10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product which is chromagraphed on silica gel (70-230 mesh, 10 g), eluding with methanol/methylene chloride (7.5/92.5). Pooling and concentration of those fractions with an Rf =0.67 by TLC (methanol/chloroform, 10/90) and recrystallization from chloroform/diethyl ether gives the title compound, mp 290-292 C.

As the paragraph descriping shows that 21169-71-1 is playing an increasingly important role.

Reference£º
Patent; Pharmacia & Upjohn Company; US5968962; (1999); A;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3405-77-4,5-Methylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

5-Methylisoxazole-3-carboxylic acid (150 mg, 1.18 mmol) dissolved in toluene (2 mL) was treated with DMF (1 drop) and thionyl chloride (1.42 mmol, 103 Iota then heated to reflux for 5 h. The solvent was removed in vacuo to afford crude 5-methylisoxazole-3- carbonyl chloride (155 mg, 1.06 mmol) as a brown oil. The crude acid chloride without purification was dissolved in THF (4 mL), treated with Et3N (155 mu, i.o6 mmol) and stirred for 5 min, before adding 4-(2-aminoethyl)benzenesulfonamide (220 mg, 1.10 mmol) and stirring at room temperature for 15 h under N2 atmosphere. The reaction mixture was concentrated in vacuo and purified by MPLC, affording the titled compound as an amorphous white solid (205 mg, 62%): NMR (600 MHz, DMSO- d6) delta 8.79 (t, J = 5-8 Hz, lH), 7-74 (d, J = 8.3 Hz, 2H), 7.41 (d, J = 8.3 Hz, 2H), 7.30 (s, 2H), 6.50 (q, J= 0.8 Hz, lH), 3.49 (m, 2H), 2.91 (t, J = 7.2 Hz, 2H), 2.45 (d, J= 0.8 Hz, 3H); ^C NMR (151 MHz, DMSO-d6) delta 171.0, 158.8, 158.5, 143-3, 142.0, 129.0, 125. 6, 101.1, 39-8, 34-3, H-7; HRMS (ESI-TOF) m/z calcd for C13H14N304S [M-H]- 308.0711, found 308.0708; LC-MS m/z 308.0 [M+H]+, purity >99% (ELSD).

The synthetic route of 3405-77-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; THE UNIVERSITY OF QUEENSLAND; THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN; O’NEILL, Luke; COLL, Rebecca; COOPER, Matthew; ROBERTSON, Avril; SCHRODER, Kate; MACLEOD, Angus Murray; MILLER, David John; (109 pag.)WO2018/215818; (2018); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

3405-77-4, 5-Methylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5-methylisoxazole-3-carboxylic acid (1.5 g, 12.04 mmol) was added to a mixture of potassium nitrate (1.83 g, 18.06 mmol) and sulfuric acid (5 ml) at room temperature. After complete dissolution, the mixture was warmed to 50¡ãC and stirred for 4 hours. The mixture was then cooled to 0¡ãC, ice was added, and the solution was neutralized with sodium bicarbonate. The mixture was extracted with ethyl acetate (3 x 30 ml), dried over sodium sulfate, filtered and concentrated to give 1.45 g of 4 as a white solid (8.43 mmol, 70percent). The product could be further recrystallized from dichloromethane.

3405-77-4 5-Methylisoxazole-3-carboxylic acid 76947, aIsoxazoles compound, is more and more widely used in various.

Reference£º
Article; Wei?wer, Michel; Bittker, Joshua A.; Lewis, Timothy A.; Shimada, Kenichi; Yang, Wan Seok; MacPherson, Lawrence; Dandapani, Sivaraman; Palmer, Michelle; Stockwell, Brent R.; Schreiber, Stuart L.; Munoz, Benito; Bioorganic and Medicinal Chemistry Letters; vol. 22; 4; (2012); p. 1822 – 1826;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1136-45-4,5-Methyl-3-phenylisoxazole-4-carboxylic acid,as a common compound, the synthetic route is as follows.

A mixture of 406 mg (2 mmol) 5-methyl-3-phenyl-isoxazole-4-carboxylic acid (commercially available) and 4 mL SOCl2 was heated to reflux for 3 h. After evaporation of all volatiles the residue was added to a mixture of 206 mg (2 mmol) 1H-pyrrole-2-carboxylic acid methyl ester (commercially available) and 440 mg (3 mmol) AMCl3 in 25 mL dichloroethane and heated to reflux for 3 h. After cooling to room temperature the precipitate was collected and washed with dichloromethane. The residue was purified on silica eluting with a gradient of ethyl acetate and heptane affording 210 mg (37%) of the title compound as white foam. (m/e): 311.0 (MH+; 100%).

1136-45-4 5-Methyl-3-phenylisoxazole-4-carboxylic acid 14343, aIsoxazoles compound, is more and more widely used in various.

Reference£º
Patent; Buettelmann, Bernd; Han, Bo; Knust, Henner; Nettekoven, Matthias Heinrich; Thomas, Andrew William; US2007/66668; (2007); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem